US FDA approves Vertex gene therapy for sickle cell in children as young as 2

• In clinical trials, all 8 evaluable children aged 5-12 with sickle cell disease experienced no severe painful crises for at least 12 consecutive months within 24 months of treatment
• For beta thalassemia, 8 of 9 evaluable children achieved transfusion independence for 12 consecutive months, with median duration of 20.1 months
• Casgevy is a one-time treatment made from a patient's own blood stem cells, offering an alternative to bone marrow transplants which require matching donors

Summary

Key Development: The U.S. FDA approved expanded use of Vertex Pharmaceuticals' gene therapy Casgevy for children as young as 2 years old with sickle cell disease and beta thalassemia, making it the first such treatment cleared for this age group. The therapy was previously approved only for patients aged 12 and older.

Treatment Details: Casgevy is a one-time gene therapy manufactured from a patient's own blood stem cells, designed to treat inherited blood disorders including sickle cell disease and transfusion-dependent beta thalassemia.

Clinical Trial Results:

• Sickle Cell Disease: All 8 evaluable pediatric patients (ages 5-12) experienced zero severe vaso-occlusive crises or painful episodes for at least 12 consecutive months within the first 24 months post-infusion
• Beta Thalassemia: 8 of 9 evaluable children achieved transfusion independence for 12 consecutive months, with median duration of 20.1 months

Regulatory Context: The FDA granted approval in just 53 days using the Commissioner's National Priority Voucher, a fast-track program designed to expedite drug application reviews. In 2023, the FDA initially approved gene therapies from both Vertex and Genetix Biotherapeutics for sickle cell disease patients 12 years and older.

Market Implications: This expanded approval significantly broadens Vertex's addressable patient population for Casgevy, potentially capturing the pediatric market earlier than competing treatments. Traditional alternatives include bone marrow transplants (requiring matched donors) and hydroxyurea chemotherapy, positioning Casgevy as a potentially transformative treatment option for young patients with these debilitating inherited blood disorders.